Nascent Biotech Inc., of San Diego, said it has manufactured enough product to complete initial phase I/II trials of pritumumab, a fully human monoclonal antibody, in brain cancers, with more than adequate amounts left over to initiate trials in other epithelial cancers such as breast, lung, colon and pancreas.